Skip to main content

Table 4 Metabolic alterations in ERG Rearrangement-positive PC versus ERG Rearrangement-negative PC

From: Comprehensive metabolomics analysis of prostate cancer tissue in relation to tumor aggressiveness and TMPRSS2-ERG fusion status

Metabolite Change in ERG-positive PC Technique BH p-valuea BH p-value for mixed model BH p-value for mixed model adjusted for Gleason score BH p-value for mixed model adjusted for percentage of epithelium BH p-value for mixed model adjusted for percentage of malignancy
Glycerophosphocholine 1H HR MAS NMR 7.05 × 10−3 4.50 × 10−01 7.69 × 10− 01 4.03 × 10− 01 3.79 × 10− 01
O-Phosphocholine 1H HR MAS NMR 2.96 × 10− 2 5.43 × 10− 01 7.47 × 10− 01 5.31 × 10− 01 5.47 × 10− 01
Lysine 1H HR MAS NMR 1.64 × 10− 2 8.85 × 10− 02 6.46 × 10− 01 1.05 × 10− 02 2.00 × 10− 02
Tyrosine 1H HR MAS NMR 8.74 × 10− 3 1.54 × 10− 03 2.40 × 10− 01 1.54 × 10− 03 2.81 × 10− 03
Myo-inositol 1H HR MAS NMR 4.73 × 10−3 3.00 × 10− 02 2.99 × 10− 01 5.09 × 10− 02 5.82 × 10− 02
Valine 1H HR MAS NMR 1.81 × 10− 2 6.91 × 10− 02 6.46 × 10− 01 3.09 × 10− 02 3.54 × 10− 02
Phenylalanine 1H HR MAS NMR 3.52 × 10− 2 1.34 × 10− 02 2.89 × 10− 01 1.39 × 10− 02 2.00 × 10− 02
Hypoxanthine 1H HR MAS NMR 1.71 × 10− 2 8.23 × 10− 02 6.13 × 10− 01 7.59 × 10− 02 4.68 × 10− 02
Ascorbate 1H HR MAS NMR 3.57 × 10− 2 3.20 × 10− 01 7.69 × 10− 01 4.03 × 10− 01 2.81 × 10− 01
Glutathione 1H HR MAS NMR 3.57 × 10− 2 3.66 × 10− 01 7.95 × 10− 01 4.93 × 10− 01 4.03 × 10− 01
Aspartate 1H HR MAS NMR 4.15 × 10− 2 2.74 × 10− 01 7.69 × 10− 01 2.92 × 10− 01 4.28 × 10− 01
Butyrylcarnitine LC-MS (+) 6.90 × 10− 4 1.63 × 10− 01 3.46 × 10− 01 1.57 × 10− 01 1.57 × 10− 01
Myristoylcarnitine LC-MS (+) 3.06 × 10− 4 8.85 × 10− 02 1.88 × 10− 01 5.99 × 10− 02 3.76 × 10− 02
Hexanoylcarnitine LC-MS (+) 6.90 × 10− 4 2.30 × 10− 01 6.08 × 10− 01 2.50 × 10− 01 2.42 × 10− 01
Xanthine LC-MS (+) 2.84 × 10−4 8.97 × 10− 04 3.42 × 10− 03 1.54 × 10− 03 2.81 × 10− 03
Acetylcarnitine LC-MS (+) 3.46 × 10− 4 9.15 × 10− 01 3.31 × 10− 01 9.77 × 10− 02 1.12 × 10− 01
Adenine LC-MS (+) 1.55 × 10− 3 1.75 × 10− 01 2.89 × 10− 01 1.69 × 10− 01 1.57 × 10− 01
Palmitoylcarnitine LC-MS (+) 2.76 × 10− 3 1.78 × 10− 01 2.89 × 10− 01 1.26 × 10− 01 1.27 × 10− 01
Sphingosine LC-MS (+) 8.34 × 10− 3 2.75 × 10− 01 6.13 × 10− 01 3.32 × 10− 01 3.08 × 10− 01
Dodecanoylcarnitine LC-MS (+) 2.58 × 10− 3 2.67 × 10− 01 4.73 × 10− 01 2.92 × 10− 01 2.34 × 10− 01
Oleoylcarnitine LC-MS (+) 1.70 × 10− 2 4.77 × 10− 01 5.60 × 10− 01 3.61 × 10− 01 3.36 × 10− 01
Stearoylcarnitine LC-MS (+) 4.26 × 10− 3 1.81 × 10− 01 2.89 × 10− 01 1.25 × 10− 01 1.27 × 10− 01
Inosine LC-MS (+) 8.44 × 10− 4 1.78 × 10− 01 4.73 × 10− 01 1.80 × 10− 01 1.89 × 10− 01
Propionylcarnitine LC-MS (+) 2.90 × 10−2 4.05 × 10− 01 7.35 × 10− 01 4.22 × 10− 01 4.03 × 10− 01
Uric acid LC-MS (+) 2.16 × 10− 3 1.75 × 10− 01 4.73 × 10− 01 1.57 × 10− 01 1.83 × 10− 01
  1. BH Benjamini–Hochberg multiple testing correction; a nonparametric t-test